At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 216 enrolled
Drug / intervention
Anidulafungin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations
In Brief
A Phase 3 clinical trial evaluating Anidulafungin, Fluconazole, and 1 other intervention for Invasive Candidiasis. Completed, enrolled 216 participants across 61 sites in 19 countries.
Detailed Summary
To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Candidiasis
CountriesAustria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Russia, Slovakia, Turkey (Türkiye), Ukraine, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJul 2008
Primary CompletionMay 2010
TodayJul 2026
First PostedJun 3, 2008
Enrollment StartJul 1, 2008
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.1 years ago
Interventions
Anidulafungindrug
Anidulafungin Intravenous Administration
Fluconazoledrug
Oral Administration of Fluconazole
Voriconazoledrug
Oral Administration of Voriconazole